anti CD19 CAR NK cells
2023-SR-834
Phase 1 mab active
Quick answer
anti CD19 CAR NK cells for Antisynthetase Syndrome is a Phase 1 program (mab) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- Antisynthetase Syndrome
- Phase
- Phase 1
- Modality
- mab
- Status
- active